MedElevator
Войти в исследования European journal of preventive cardiology · 2026
Efficacy and Safety of Oral PCSK9 Inhibitors: Insights from a Meta-analysis of RCTS.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Olmastroni Elena, Xie Sining, Galimberti Federica, Catapano Alberico L, Casula Manuela
Аннотация
AIM: Current proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors (the monoclonal antibodies evolocumab and alirocumab, and the siRNA inclisiran) require parenteral administration, which may limit long-term adherence. Orally active PCSK9 inhibitors could improve convenience and treatment accessibility. This meta-analysis evaluates LDL-C reduction and other lipid changes reported in randomized controlled trials (RCTs) of oral PCSK9 inhibitors.
METHODS: RCTs comparing oral PCSK9 inhibitors with placebo and reporting LDL-C changes were identified through PubMed, EMBASE, Web of Science, CENTRAL, and ClinicalTrials.gov up to November 2025. Pooled mean percentage changes in lipid parameters were calculated using random- and fixed-effects models. Serious adverse events (SAEs) were analysed using risk ratios (RRs) with 95% confidence intervals (CIs).
RESULTS: Five RCTs on three different molecules (enlicitide, NNC0385-0434, and laroprovstat), including a total of 3,295 participants with hypercholesterolemia receiving stable doses of background lipid-lowering therapy prior to study initiation, met the inclusion criteria. Treatment durations ranged from 8 to 24 weeks. Pooled analysis showed a significant LDL-C reduction of -59.31% (95% CI -62.33 to -56.28) compared with placebo. Additional lipid parameters also improved: apolipoprotein B (-49.53%, 95% CI -54.19 to -44.79), non-HDL cholesterol (-55.41%, 95% CI -57.35 to -53.48), and Lipoprotein(a) (-22.74%, 95% CI -26.67 to -18.81). The pooled RR for SAEs was 0.84 (95% CI 0.68-1.03; p = 0.41), indicating no increased risk versus placebo.
CONCLUSIONS: Oral PCSK9 inhibitors demonstrate potent LDL-C-lowering efficacy, comparable to parenteral PCSK9i, with favourable effects on other atherogenic lipids and a reassuring short-term safety profile.
METHODS: RCTs comparing oral PCSK9 inhibitors with placebo and reporting LDL-C changes were identified through PubMed, EMBASE, Web of Science, CENTRAL, and ClinicalTrials.gov up to November 2025. Pooled mean percentage changes in lipid parameters were calculated using random- and fixed-effects models. Serious adverse events (SAEs) were analysed using risk ratios (RRs) with 95% confidence intervals (CIs).
RESULTS: Five RCTs on three different molecules (enlicitide, NNC0385-0434, and laroprovstat), including a total of 3,295 participants with hypercholesterolemia receiving stable doses of background lipid-lowering therapy prior to study initiation, met the inclusion criteria. Treatment durations ranged from 8 to 24 weeks. Pooled analysis showed a significant LDL-C reduction of -59.31% (95% CI -62.33 to -56.28) compared with placebo. Additional lipid parameters also improved: apolipoprotein B (-49.53%, 95% CI -54.19 to -44.79), non-HDL cholesterol (-55.41%, 95% CI -57.35 to -53.48), and Lipoprotein(a) (-22.74%, 95% CI -26.67 to -18.81). The pooled RR for SAEs was 0.84 (95% CI 0.68-1.03; p = 0.41), indicating no increased risk versus placebo.
CONCLUSIONS: Oral PCSK9 inhibitors demonstrate potent LDL-C-lowering efficacy, comparable to parenteral PCSK9i, with favourable effects on other atherogenic lipids and a reassuring short-term safety profile.